Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma

Poorly differentiated esophageal adenocarcinoma (PDEAC) has a dismal prognosis. Glypican-1(GPC-1) is known to be upregulated in several cancer types in contrast to healthy tissues, rendering it as a biomarker. Nevertheless, the potential therapeutic targeting of GPC-1 has not been explored in PDEAC....

Descripción completa

Detalles Bibliográficos
Autores principales: Pratap, Akshay, Qualman, Andrea, Garrett, Hedlund, Westbrook, Lindsey, The, Erlinda, Mitra, Sanchayita, Cordero, Mila, Monge, Kenneth Meza, Idrovo, Juan- Pablo, Chauhan, Argudit, Cheng, Linling, Cohen, Mitchell Jay, Mungo, Benedetto, Wani, Sachin, Meguid, Robert Alexander, McCarter, Martin D, Meng, Xianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464651/
https://www.ncbi.nlm.nih.gov/pubmed/37649964
http://dx.doi.org/10.1080/23723556.2023.2238873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464651/
https://www.ncbi.nlm.nih.gov/pubmed/37649964
http://dx.doi.org/10.1080/23723556.2023.2238873

Ejemplares similares